Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03909529
Other study ID # C-CMP-SPI-001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 10, 2019
Est. completion date April 30, 2019

Study information

Verified date June 2022
Source CMP Development, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An open label, balanced, randomized, single-dose, two-treatment, two-sequence, two-period, crossover oral drug-drug interaction study of spironolactone (perpetrator) and Digoxin (substrate drug) in healthy adult human subjects under fasting condition.


Description:

Drug interaction studies between spironolactone and digoxin, particularly studies in which digoxin was administered intravenously (Waldorf, S 1978; Fenster, P.E. 1984), indicate that spironolactone may decrease the renal clearance of digoxin by 18-25%, and increase the (area under curve) AUC of digoxin by 35-44%. Although the radioimmunoassay used in the study may be confounded, these results suggest that inhibition of P-gp in the renal proximal tubules may be possible. To account for possible renal P-gp inhibition, subjects in the test group will be pretreated with spironolactone for about 5 days to allow accumulation of some of the metabolites which have a long half-life (e.g., canrenone ~33 hours) and continue to be treated with spironolactone while digoxin is renally eliminated from the body. Based on this assessment, the FDA suggested study design is Treatment A: Single dose of digoxin alone. Treatment B: Digoxin + Spironolactone; Day 1- 9: Spironolactone single dose; Day 6: Digoxin single oral dose. Also, digoxin has a long half-life of 1.5-2 days, and the Pharmacokinetic (PK) sampling scheme of up to 72 hours may not be enough to characterize the elimination kinetics of digoxin. Hence, the plasma concentrations of digoxin up to 96 hours (4 days) postdose is considered This will allow you to detect possible differences in the clearance of digoxin mediated by an interaction with P-gp in the renal proximal tubules. The study also involves collecting urine samples and measuring renal clearance (CLR) and unchanged drug excreted in urine (fe) for digoxin.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date April 30, 2019
Est. primary completion date April 19, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria: - Healthy human subjects aged between 20 and 35 years (including both). - Subjects with a BMI between 18.5 - 24.9 Kg/m2 (including both) but body weight not less than 60 Kgs. - Subjects who were screened at least 48 hours prior to check-in - Subjects with normal health as determined by personal medical history, clinical examination, and laboratory examinations including serological tests during the screening - Subjects with normal 2D echo - Subjects having normal 12-lead electrocardiogram (ECG) or ECG with no clinical significant abnormalities as determined by Investigator. - Subjects having normal chest X-Ray (P/A view) or chest X-ray with no clinically significant abnormalities as determined by investigator. - Subjects able to communicate effectively. - Subjects willing to give written informed consent and adhere to all the requirements of this protocol. - Additional inclusion criteria for female subjects, Female of childbearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence: or Postmenopausal for at least 1 year, or Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed on the subject). Exclusion Criteria: - Subjects having contraindications or hypersensitivity to study drug or related group of drugs. - History or presence of any medical condition or disease according to the opinion of the physician. - History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder. - Subject having QT/ corrected QT interval (QTc) >450 milliseconds - History or presence of significant alcoholism or drug abuse in the past one year. - History or presence of significant smoking (more than 10 cigarettes /day or consumption of tobacco products). - Subjects who fail to abstain from consuming any alcoholic products from 48.00 hours prior to check-in to till check-out / last sample of the study. - Subjects who fail to abstain from any xanthine-containing food and/or beverages (like chocolate, tea, coffee, cola drinks), cigarettes and tobacco containing products and grapefruit and/or it's juice from 48.00 hours prior to check-in to till check-out / last sample of the study. - Subjects who fail to refrain from pan or pan masala, gutkha, masala (containing beetle nut and tobacco) for 48.00 hours prior to check-in to till check-out/last sample of the study. - Difficulty with donating blood. - Systolic blood pressure less than 110 mm Hg or more than 140 mm Hg. - Diastolic blood pressure less than 70 mm Hg or more than 90 mm Hg. - Pulse rate less than 60 beats/minute or more than 100 beats/minute. - Use of any prescribed medication during last two weeks or over-the- counter (OTC) medicinal products/ herbal products during the last one week prior to check-in. - Major illness during 90 days before check-in. - Participation in a drug research study within past 90 days of check-in. - Donation of blood (i.e. one unit or 350 mL) in the past 90 days before check-in. - History of unusual diet consumption in the past 3 weeks before check-in. - Additional exclusion criteria for female subjects, Volunteer demonstrating a positive pregnancy test. Volunteers who are pregnant, currently breast-feeding or who are likely to become pregnant during the study. Volunteers who have used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 14 days before dosing. -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Digoxin 250 MCG Oral Tablet
The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
Spironolactone 25 mg/ 5 mL S/F Suspension
The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension

Locations

Country Name City State
India ClinSync Clinical Research Pvt. Ltd. Hyderabad, Telangana

Sponsors (1)

Lead Sponsor Collaborator
CMP Development, LLC

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Other Renal Clearance (CLR)/Percent Recovered Summary Statistics for Untransformed Urine PK Parameters of digoxin Per Treatment-Renal clearance (CLR)/Percent Recovered 04 Days
Other Unchanged Drug Excreted in Urine (fe)/ Amount Recovered Summary of Urine Pharmacokinetic parameters for digoxin -unchanged drug excreted in urine (fe)/ Amount Recovered 04 Days
Primary Dogoxin Plasma Data for Cmax Primary Pharmacokinetic parameter The following pharmacokinetic parameters for Digoxin were obtained using non-compartmental method Cmax, AUC0-96, and tmax using plasma data, Renal clearance (CLR) /Percent Recovered, Unchanged drug excreted in urine (fe)/Amount Recovered using urine data. 4 days
Primary Digoxin Plasma Data for AUC0-96 Area under the plasma concentration versus time curve from time 0 to the 96 hour time point concentration. 4 days
Secondary Digoxin Plasma Data for Tmax If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value. 4 days
Secondary ECG Measurement Will be Performed to Evaluate Any Changes in the QT Interval ECG will be performed at 1.00 and 3.00 hours post dose in each period on Day 6 and at check-out of each period of the study 4 days
See also
  Status Clinical Trial Phase
Completed NCT05574374 - Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects Phase 1
Completed NCT04557397 - Fruquintinib CYP3A Inhibitor and Inducer Study Phase 1
Completed NCT06031454 - Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin Phase 1
Completed NCT05137600 - A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects Phase 1
Recruiting NCT06119958 - Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects Phase 1
Active, not recruiting NCT05812404 - Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects Phase 1
Completed NCT04606537 - Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects Phase 1
Completed NCT04939467 - Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT04542252 - Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects Phase 1
Enrolling by invitation NCT06037564 - B-free Multistage Trial Phase 4
Completed NCT05123820 - Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470 Phase 1
Recruiting NCT04840862 - Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Phase 4
Completed NCT04814498 - Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT01350921 - Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers Phase 1
Completed NCT03103568 - A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers Phase 1
Completed NCT04840641 - Flucloxacillin as an Inducer of CYP-enzymes Phase 1
Completed NCT05860114 - Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3) Phase 1
Completed NCT05304845 - Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects Phase 1
Completed NCT05845567 - The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2) Phase 1
Completed NCT04776499 - Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers Phase 1